Zacks Small Cap Has Pessimistic View of ABEO FY2027 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Investment analysts at Zacks Small Cap cut their FY2027 earnings estimates for Abeona Therapeutics in a report issued on Friday, November 14th. Zacks Small Cap analyst D. Bautz now expects that the biopharmaceutical company will post earnings of $1.91 per share for the year, down from their previous forecast of $2.15. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share.

A number of other equities analysts also recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a report on Monday, October 13th. Weiss Ratings lowered Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 24th. Oppenheimer raised their price objective on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, August 15th. Finally, Wall Street Zen lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Abeona Therapeutics Trading Down 1.8%

ABEO opened at $4.45 on Monday. The company has a current ratio of 6.73, a quick ratio of 6.65 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average price of $5.34 and a two-hundred day moving average price of $5.97. The company has a market cap of $241.15 million, a P/E ratio of 6.36 and a beta of 1.45. Abeona Therapeutics has a 1-year low of $3.93 and a 1-year high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17.

Insider Buying and Selling

In related news, CFO Joseph Walter Vazzano sold 9,035 shares of the company’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $5.39, for a total value of $48,698.65. Following the transaction, the chief financial officer owned 453,631 shares in the company, valued at $2,445,071.09. The trade was a 1.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brendan M. O’malley sold 9,366 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $5.39, for a total value of $50,482.74. Following the completion of the transaction, the senior vice president directly owned 350,763 shares in the company, valued at $1,890,612.57. This trade represents a 2.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 78,612 shares of company stock worth $410,271 over the last three months. 6.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ABEO. Ameritas Investment Partners Inc. purchased a new position in shares of Abeona Therapeutics during the 2nd quarter valued at about $25,000. Legal & General Group Plc purchased a new position in Abeona Therapeutics during the 2nd quarter valued at approximately $27,000. Russell Investments Group Ltd. bought a new stake in Abeona Therapeutics in the third quarter worth $37,000. Legato Capital Management LLC bought a new stake in shares of Abeona Therapeutics in the 3rd quarter worth about $57,000. Finally, Riverwater Partners LLC purchased a new stake in Abeona Therapeutics during the second quarter valued at approximately $62,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.